Aptevo Therapeutics Inc APVO

Healthcare Biotechnology

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

NDAQ:APVO - Post by User

Aptevo Therapeutics Inc > Why Aptevo Therapeutics Stock Is Cratering | Benzinga

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Apr 12, 2024 11:05am

47 Views

Post# 35985685

RE:Why Aptevo Therapeutics Stock Is Cratering | Benzinga

I'd say The Maggot has to change the way he does RS's......people start to catch on to the way Mr. M works.

Surprise the masses...whodda thunk that the Powers to Be would do a financing that low

Fooled me......down but not out

I swear revenge will be sweet ; )

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario